egfr in 12

EGFR-IN-12 (EGFR Inhibitor) is a cell permeable and selective inhibitor of EGFR kinase (IC50: 21 nM) and blocks receptor autophosphorylation in cells.

EGFR HER2-IN-12 (compound 14b) serves as a dual inhibitor targeting EGFR and HER2, demonstrating 81% and 51% inhibition respectively at a concentration of 10 μM. This compound exhibits minimal toxicity towards A431 and MDA-MB-361 cancer cells [1].

Mutated EGFR-IN-3 is a ATP-competitive and highly selective allosteric dibenzodiazepinone EGFR(L858R T790M) and EGFR(L858R T790M C797S) inhibitor(IC50 of 12 nM and 13 nM, respectively. )

ZN-A-1041 is an inhibitor of HER2 in BT474 cells with an IC50 of 9.5 nM and wt-EGFR in H838 cells with an IC50 of 12 μM. It can be utilized for cancer and inflammation research [1].

Anticanceragent 231 (compound P5) is a tyrosine kinase inhibitor with an IC50 value of 3.95 μM. It targets the EGFR-ERK1 2 signaling pathway, reducing cell viability, proliferation, migration, and cancer stemness in triple-negative breast cancer (TNBC) cells, potentially playing a significant role in the treatment of TNBC.

Osimertinib-d6 is a deuterated compound of Osimertinib. Osimertinib has a CAS number of 1421373-65-0. Osimertinib is a small molecule tyrosine kinase receptor inhibitor and antineoplastic agent that is used in the therapy of selected forms of advanced non-small cell lung cancer (NSCLC).